A Phase 3 interventional study of Lidocaine 8mg + CPC 2mg and Lidocaine 1mg + CPC 2mg in Sore Throat Due to a Common Cold, sponsored by Novartis. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Respiratory Tract Infections with a site in Germany — 7 open to participants now, 8 under way, 4 of them phase 3. Respiratory Tract Infections · Germany.
Among the 38 studies in Respiratory Tract Infections with a site in Germany, this one is the 15th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2010, is one of 15 in phase 3, and was the 5th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
Browse Respiratory Tract Infections studies →7 of the 38 studies in Respiratory Tract Infections with a site in Germany are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in Germany, United States, France and 2 more countries
Ages 60+
Pfizer · Sites in Germany, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Germany, United States, Argentina and 16 more countries
Ages 12+
Universität des Saarlandes · Sites in Germany
Ages 5 mo+
AstraZeneca · Sites in Germany, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 15 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 250 across the 29 interventional studies, 702 across the 9 observational. Of the 29 that completed or were terminated, 9 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 5 studies filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Respiratory Tract Infections with a site in Germany that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04769037Helmholtz Zentrum MünchenSupplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in Respiratory Tract Infections with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
This study's enrollment of 250 is above the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Browse Respiratory Tract Infections studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Compared within Respiratory Tract Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pharyngitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
one single dose
Drug: Lidocaine 8mg + CPC 2mg
one single dose
Drug: Lidocaine 1mg + CPC 2mg
Change From Baseline Sore Throat Pain Intensity
100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm)
Time frame: Baseline and 2 hours post-dose
Change From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose
100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm). It measures the highest pain level felt by the patient.
Time frame: Baseline and 240 mn post-dose
14 Dec 2010 to 5 Apr 2011
| Milestone | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg |
|---|---|---|
| Started | 125 | 125 |
| Completed | 124 | 125 |
| Not completed | 1 | 0 |
100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm)
| mm | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg |
|---|---|---|
| Change From Baseline Sore Throat Pain Intensity | -27.4 (-31.0 to -23.8) | -26.9 (-30.5 to -23.3) |
100 milimeter (mm) visual acuity score (left=no pain=0mm, right=worst possible pain=100mm). It measures the highest pain level felt by the patient.
| mm | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg |
|---|---|---|
| Change From Baseline Sore Throat Pain Intensity up to 240 mn Post-dose | -25.5 (-29.8 to -21.2) | -29.1 (-33.1 to -25.1) |
Collected over 14 Dec 2010 to 5 Apr 2011. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lidocaine 8mg +CPC 2mg | — | 1/125 (0.8%) | 10/125 (8%) |
| Lidocaine 1mg + CPC 2mg | — | 0/125 (0%) | 9/125 (7.2%) |
| Event | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg |
|---|---|---|
| Tendon ruptureInjury, poisoning and procedural complications | 1/125 | 0/125 |
| Event | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg |
|---|---|---|
| HeadacheNervous system disorders | 7/125 | 6/125 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 1/125 | 1/125 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/125 | 1/125 |
| dizzinessNervous system disorders | 0/125 | 1/125 |
| hyperaesthesiaNervous system disorders | 1/125 | 0/125 |
| RashSkin and subcutaneous tissue disorders | 1/125 | 0/125 |
| StridorRespiratory, thoracic and mediastinal disorders | 1/125 | 0/125 |
| vertigoNervous system disorders | 1/125 | 0/125 |
| Age, Categorical(Participants) | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 125 | 125 | 250 |
| >=65 years | 0 | 0 | 0 |
| Age Continuous(years) | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg | Total |
|---|---|---|---|
| Mean | 32.1 ± 12.6 | 31.6 ± 11.6 | 31.9 ± 12.1 |
| Sex: Female, Male(Participants) | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg | Total |
|---|---|---|---|
| Female | 67 | 67 | 134 |
| Male | 58 | 58 | 116 |
| Region of Enrollment(participants) | Lidocaine 8mg +CPC 2mg | Lidocaine 1mg + CPC 2mg | Total |
|---|---|---|---|
| Germany | 125 | 125 | 250 |
The record gives a start of Dec 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Respiratory Tract Infections →